Pictet Asset Management SA lifted its position in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 0.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 670,084 shares of the company’s stock after acquiring an additional 3,617 shares during the quarter. Pictet Asset Management SA owned approximately 0.83% of Vaxcyte worth $25,115,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in PCVX. Carlyle Group Inc. bought a new position in Vaxcyte during the first quarter valued at about $72,080,000. Jennison Associates LLC bought a new position in Vaxcyte during the fourth quarter valued at about $68,185,000. Braidwell LP bought a new position in Vaxcyte during the fourth quarter valued at about $65,321,000. RA Capital Management L.P. grew its position in Vaxcyte by 27.9% during the fourth quarter. RA Capital Management L.P. now owns 5,857,459 shares of the company’s stock valued at $280,865,000 after buying an additional 1,276,256 shares during the period. Finally, Avidity Partners Management LP grew its position in Vaxcyte by 156.9% during the fourth quarter. Avidity Partners Management LP now owns 1,615,400 shares of the company’s stock valued at $77,458,000 after buying an additional 986,700 shares during the period. Institutional investors own 89.22% of the company’s stock.
Analyst Ratings Changes
Several equities analysts recently weighed in on PCVX shares. 888 restated a “reiterates” rating on shares of Vaxcyte in a research report on Tuesday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price objective on shares of Vaxcyte in a report on Wednesday, August 9th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte currently has a consensus rating of “Buy” and an average price target of $65.00.
Vaxcyte Stock Up 5.1 %
NASDAQ PCVX opened at $49.82 on Friday. Vaxcyte, Inc. has a 52 week low of $20.49 and a 52 week high of $54.97. The firm’s 50-day simple moving average is $49.04 and its two-hundred day simple moving average is $45.57.
Vaxcyte (NASDAQ:PCVX – Get Free Report) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.04. As a group, research analysts forecast that Vaxcyte, Inc. will post -3.07 EPS for the current fiscal year.
Vaxcyte Company Profile
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Stories
- Five stocks we like better than Vaxcyte
- Market Cap Calculator: How to Calculate Market Cap
- MarketBeat Week in Review – 8/14 – 8/18
- What Are Utility Stocks? An Overview of the Utilities Sector
- 8 Best Artificial Intelligence Stocks Under $10
- How to Invest in the Best Canadian Stocks
- What Ross Stores Earnings Say About The Saver Shopping Economy
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
